1

NOTICE FOR THESIS WRITING (M.Pharm 2010-12 Batch)

(Necessary Certificate Required & Thesis Writing Format)

This is to inform all M.Pharm final year students that, the thesis should contain the

following certificates and must be formatted as per given instruction from UTU,

Dehradun;

1. Attendance certificate for 46 weeks (from commencement of IIIrd semester).

2. Any project work less than 16 weeks of study: Necessary of justification &

clarification for remaining 26 weeks, must be submitted under counter sign

by supervision/Guide/HOD of concern Institute.

3. Project/Dissertation work completion certificate should be of a project, not of

training.

4. Plant authentication (if thesis works on any plant) and animal ethical

clearance certificates (in original) are necessary with thesis.

5. All certificates must be signed by respective Supervisor/Guide/Co-

guide/Head of Institution.

Note: Please refer to Ordinance of M. Pharm U.T.U.

PRINCIPAL

2

INSTRUCTIONS TO CANDIDATES Paper Use only one side of high quality, plain white (unlined in any way) bond paper, minimum 20-lb weight, and 8.5” x 11” in size. Erasable paper should not be used. Type Size and Print

• Select fonts type Times New Roman and size of 10 to 12 characters. • The size of the titles should be 14 and bold. • The size of subtitles should be 12 and bold. • Print should be letter quality of laser printing.

Spacing Use double spacing except for ling quotations, footnotes and endnotes. Margins

• The left hand margin must be 1.5”. • Other margins should be 1.0”. • Diagrams, photographs or facsimiles in any form should be a standard page size or

if larger, folded so that a free left hand margin of 1.5” remains. • The folded sheet is not larger than the standard page.

Photographs

• Professional quality black and white/colour photographs are necessary for clear reproduction.

• You should be certain the coloured figure will copy clearly and will not be confusing when printed in black and white.

File Format

• Thesis or Dissertations format should be in .Doc (Ms Word Document) or PDF. • Image files in JPG or TIFF format and Audio Visual in AVI (Audio video

interleave),GIF, MPEG (moving picture expert) files format. Labeling on CD

CD-Rom labeling should be standard and should contain:- 1. Title 2. Subtitle 3. Name of the candidate 4. Degree name 5. Subject name 6. Guide name 7. Name of the department 8. College 9. Place 10. Session.

3

---------------------------TITLE ------------------------------ ---------------------------Subtitle----------------------------

By

Name of the Candidate (Roll No.:……………..)

Dissertation Submitted to the

Uttarakhand Technical University, Dehradun (UK)

In partial fulfillment of the requirements for the degree of

Master of Pharmacy

in {PHARMACOLOGY}

Under the supervision of Under co-supervision of Name of the supervisor & Addr. Name of the co-supervi. & Addr.

Siddhartha Institute of Pharmacy, Sahastradhara Road, I.T. Park

Dehradun (UK)

SEPTEMBESEPTEMBESEPTEMBESEPTEMBERRRR 2012201220122012 (Note: This Page, for those students who doing their project inside the campus)

4

---------------------------TITLE ------------------------------ ---------------------------Subtitle----------------------------

By

Name of the Candidate (Roll No.:……………..)

Dissertation Submitted to the

Uttarakhand Technical University, Dehradun (UK)

In partial fulfillment of the requirements for the degree of

Master of Pharmacy

in {PHARMACOLOGY}

Under the supervision of Name of the supervisor & Full Address

With mail ID.

Name & address of the respective Organisation/Institute

SEPTEMBESEPTEMBESEPTEMBESEPTEMBERRRR 2012201220122012 (Note: This Page, for those students who doing their project outside the campus)

5

ENDORSEMENT BY THE DIRECTOR, PRINCIPAL/HEAD OF THE

INSTITUTION

This is to certify that the dissertation entitled “ -------------------------Title- -----------

-------------------------------------“ is a research work carried by Name of the

Candidate in partial fulfillment of the requirement for the degree of Post Graduate

Degree in Pharmacy (Pharmacology), under the guidance of Name & designation

of the Guide, as per the given certificate/documents by the candidate.

Seal & Signature of the Principal Date:

Place:

6

CERTIFICATE BY THE GUIDE

This is to certify that the dissertation/project entitled “-----------------Title- ----------

----------------------“ is an Original Research Work carried by Name of the

Candidate in partial fulfillment of the requirement for the degree of Post Graduate

Degree in Pharmacy (Pharmacology), under the guidance of Name and Address

of the respective guide.

Seal & Signature of the Guide Name Designation & Department

Date:

Place:

7

CERTIFICATE BY THE CO-GUIDE

This is to certify that the dissertation/project entitled “-----------------Title- ----------

----------------------“ is an Original Research Work carried by Name of the

Candidate in partial fulfillment of the requirement for the degree of Post Graduate

Degree in Pharmacy (Pharmacology), under the guidance of Name and Address

of the respective co-guide.

Signature of the Co-guide Name Designation & Department

Date:

Place:

Note: This certificate is required for Internal/Inside campus students only.

8

DECLARATION BY THE CANDIDATE

I hereby declare that this dissertation/ thesis entitled “------------------ Title ----------

------------“ is an original and genuine research work carried out by me under the

guidance of Name & designation of the Guide and/or Co-guide with address.

Signature of the Candidate

Date: Name

Place:

PHOTO

9

COPYRIGHT

Declaration by the Candidate

I hereby declare that the Uttarakhand Technical University, Dehradun shall have

the rights to preserve, use and disseminate the dissertation/thesis in print or

electronic format for academic/ research purpose.

Signature of the Candidate

Date: Name

Place:

©Uttarakhand Technical University, Dehradun

Note: For outside/External students only.

10

ACKNOWLDGEMENT

• Avoid Superlatives Signature of the Candidate Name

11

PREFACE

Please write in short/summary about the research work,

And about the benefited of project work for human life.

12

LIST OF ABBREVIATIONS USED (In Alphabetical Order)

Example:

% Percentage

/ Per 0C Degree celsius

Ach Acetylcholine

ANOVA Analysis of variance

B.W. Body weight

BW Body weight

CLP Ceacal ligation and puncture

DMSO Dimethyl sulphoxide

Note: It must be in alphabetical order

13

ABSTRACT

(Introduction in max. 250-350 words)

Background & Objectives

Methods

Results & Discussions

Conclusion

KEY WORDS (Max. 10)

Keywords shall be chosen from MeSH (Medical Subject Headings)

(Each keyword should be separated by semicolon)

14

TABLE OF CONTENTS

1. Preface Page No.

2. Introduction Page No. 3. Objectives Page No. 4. Review of Literature Page No. 5. Methodology Page No. 6. Results Page No. 7. Discussion Page No. 8. Conclusion Page No. 9. Summary Page No. 10. Future Scope Page No. 11. Bibliography Page No. 12. List of Papers/Patents/Presentations/Projects (if any) Page No. 13. Annexures Page No.

15

LIST OF TABLES

Sr. No.

CONTENTS PAGE NO.

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

2.0

3.1

16

LIST OF FIGURES

Sr. No. CONTENTS

PAGE NO.

1.1

1.3

1.5

1.6

1.7

1.8

2.0

3.1

3.2

3.3

3.4

3.5

4.1

4.2

4.3

17

1. Introduction

2. Aims & Objectives

3. Review of Literature

4. Resource & Methodology

5. Results

6. Discussion

7. Conclusion

8. Summary

9. Future Scope

Note: Each heading should started from new/separate page

18

10. BIBLIOGRAPHIC REFERENCES (Vancouver Format)

Reference list at end of paper

References should be numbered consecutively in the order in which they are first mentioned in the text; they should not be listed alphabetically by author or title or put in date order. Printed publications

Book- Example: Neal MJ. Medial pharmacology at a glance. Oxford; Blackwell Scientific; 1987. Rinsgiven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar publisher;1996 Note: Where there are more than six authors list the first six names, followed by et al. (and others) Government publication/ Corporate author- Example: Department of health. Saving lives: our healthier nation. London: Stationery office; 1999 (Cm 4386). Institute of Medicine (US). Looking at the future of the Medicaid program. Washington: The Institute; 1992. Report- Example: Confidential enquiries into stillbirths and deaths in infancy. 5th report. London: Stationery office; 1998. Chief Medical Officer’s Committee on Medical Aspects of Food. Nutritional aspects of the development of cancer. London: Stationery office; 1998. (Department of Health report on health and social subjects 48). Conference paper in published proceedings- Example: Bengtsson S, Solheim BG, Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors.. MEDINFO 92. Proceddings of the 7th world congress on Medical Informatics; 1992 Sep 6-10; Geneva, Switzerland, Amsterdam: North Holland: 1992; p. 1561-5: Journal article- Example: You CH, Lee KY, Chey YW, Menguy R. Electrogastrographic study of patients with unexplained nausea, bloating and vomiting. Gastroenterology 1980;79:311-4. Vega KJ, Pina 1, Krevsky B. Heart transplantation is associated with an increased risk for pancreatobilliary disease. Ann Intern Ned 1996 Jun 1; 124 (11): 980-3,

19

Parkin DM, Clayton D, Black RJ, Masuyer E, Friedl HP, Ivanov E, et al. childhood leukaemia in cander in South Africa (editorial). S Afr Med) 1994; 84:15. Note: Journal titles which are just a single word are not abbreviated. The titles of other journals should be abbreviated according to the style used in Index Medicus. Consult the list of Journals Indexed in Index Medicus, published in the January issue of Index Medicus. The list can also be obtained through the NLM= web sit (http://www.nlm.nth.gov). Newspaper article Example: Lee G. Hospitalizations tied to ozone pollution: study estimates 50,000 admissions annually. The Washington post 1996 Jun 21, Sect. A: 3 (col.5)

Electronic media Individual works Example: CDI, clinical dermatology illustrated [monograph on CD- ROM]. Receves JRT, Mailbach H. CMEA Multimedia Group, 2nd ed. Version 2.0 San Diego: CMEA; 0995. Journal article Example: Morse SS. Factors in the emergence of infectious diseases. Emerg infect Dis [serial online] 1995 Jan- Mar [cited 1996 Jun 5]; 1(1): [24screens]. Available from :URL: http://www.cdc.gov/ncidod/EID/eid.htm

Computer file Example: Hemodynamics III: the ups and sowns ofhemodynamics [computer program]. Version 2.2. Oriando (FL): computerized Educational Systmes; 1993. Website (Including the access date)

ANNEXURES (if any)

20

FORMAT FOR WRITING REFERENCE’S ABSTRACT

1. Journal: Analyst. 2012 Sep 3.

Title: Monitoring methotrexate in clinical samples from cancer patients during chemotherapy with a LSPR-based competitive sensor.

Authors: Zhao SS, Bichelberger MA, Colin DY, Robitaille R, Pelletier JN, Masson JF.

Abstract: A competitive binding assay based on localized surface plasmon resonance (LSPR) of folic acid-functionalized gold nanoparticles (FA-AuNPs) and human dihydrofolate reductase enzyme (hDHFR) was developed to detect nanomolar to micromolar concentrations of the widely applied anti-cancer drug, methotrexate (MTX). By the nature of the competitive assay for MTX, the LSPR shift from specific binding between FA-AuNPs and the free enzyme was inversely proportional to the concentration of MTX. In addition, the dynamic range for MTX was tuned from 10(-11) to 10(-6) M by varying the concentration of hDHFR from 1 to 100 nM. Inter-day reproducibility and recovery of MTX spiked in phosphate buffer saline (PBS) were excellent. Potential interferents such as FA, trimethoprim (TMP) and 4-amino-4-deoxy-N-methylpteroic acid (DAMPA) did not occur in the concentration range of interest for MTX. Clinical samples of human serum from patients undergoing MTX chemotherapy were analyzed following a simple solid-phase extraction step to isolate MTX from the serum matrix, with a limit of detection of 155 nM. Validation of the LSPR method was carried out in comparison to Fluorescence Polarization Immunoassay (FPIA), a commonly used method in clinical settings, and LC-MS/MS, a reference technique. The results of the LSPR competitive assay compared well to FPIA and LC-MS/MS, with a slope of 2.4 and 1.1, respectively, for the correlation plots. The method established herein is intended for therapeutic drug monitoring (TDM) of MTX levels in patients undergoing chemotherapy to ensure safety and efficacy of the treatment.

2. Journal: Oncol Hematol Rev. 2012 Spring;8(1):55-60.

Title: Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.

Author: Kunos CA.

Abstract: Cervical and vaginal cancers remain serious health problems. Worldwide, more than 530,000 women annually are diagnosed with these diseases, with most new incident cases occurring in nations with limited health resources and underdeveloped screening programs. For women whose disease is too bulky or widespread for surgery, radiochemotherapy should be looked upon as the standard of care. Randomized clinical trials have indicated that radiochemotherapy strategies that disrupt the repair of damaged DNA are key to the management of advanced stage cervical and vaginal cancers. Here, from a viewpoint of cancer cell molecular biology, treatments for advanced stage cervical and vaginal cancers are discussed.

21

3. Journal: Int J Mol Sci. 2012;13(7):8670-8.

Title: Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.

Authors: Worthmann H, Dengler R, Schumacher H, Schwartz A, Eisert WG, Lichtinghagen R, Weissenborn K.

Abstract: BACKGROUND: Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. METHODS: We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. RESULTS: The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217-973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004). CONCLUSION: Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.

Performa by-Mr. Harikesh Maurya